N/A N=89 Mindfulness and Mechanisms of Pain Processing in Adults With Migraines
Migraine
Primary: Change in Frequency of Migraine Days Per Month From Baseline — -1.6; -2.0 number of days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=90 pLatelEts And MigRaine iN patEnt foRamen Ovale
Platelet Aggregation, Spontaneous · Migraine With Aura · Patent Foramen Ovale
Primary: Change in Migraine Characteristics — 43; 2; 17 Participants
Phase 2 N=12 The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination
Migraine With or Without Aura
Primary: Change in Monthly Migraine Days (MMD) From Baseline to the Last 28 Days of Treatment Period. — -5.67; -3.5 days — p=0.4267
N/A N=187 The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine
Acute Migraine
Primary: Proportion of Subjects Reporting Reduction of Migraine Headache Pain at 2 Hours From Treatment Initiation — 30; 22 Participants — p=0.018
N/A N=20 Music Intervention on Migraine Headaches
Migraine Headache
Primary: Frequency of Migraine Attacks (Number of Days Per Month) — 8.45; 5.65 Number of migraine per months — p=0.012
N/A N=32 STOPAIN in the Treatment of a Single Migraine Attack
Migraine · Headache
Primary: Efficacy of STOPAIN in the Acute Treatment of Migraine — 1.92 units on a scale
N/A N=37 Study Evaluated the Effectiveness of Milnacipran to Reduce Pain Levels in Individuals With Chronic Migraine
Chronic Migraine
Primary: Change in VAS Pain Severity — 3.23; 5.36 units on a scale — p=0.1
Phase 2 N=31 Treatment of Acute Migraine Headache in Children
Migrainous Headache
Primary: The Number of Subjects With a Numeric Rating Scale Score (NRS) of Zero at Two Hours. — 5; 12 participants — p=0.03
Phase 4 N=50 Trial of Comprehensive Migraine Intervention
Migraine
Primary: Migraine Functional Impairment as Measured by Score on the Headache Impact Test 6 (HIT6) Scale — 59; 56 units on a scale
Phase 4 N=41 Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine
Chronic Migraine
Primary: Numeric Rating Scale (NRS) — 3.18; 3.78; 2.53; 3.51 units on a scale
Phase 4 N=160 Acetaminophen and Ibuprofen With and Without Magnesium and Primary Migraine in Childhood
Migraine
Primary: Pain-relief — 5.6; 5.1; 2.25; 2.2 units on a scale*hr
N/A N=100 A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache
Migraine Headache, Episodic
Primary: Change in Number of Monthly Migraine Headache Days — -3.5; -1.1 migraine days
N/A N=23 Molecular and Functional PET-fMRI Measures of Analgesia in Migraine
Migraine · Healthy
Primary: Visual Analogue Scale (VAS) 0-10 Pain Rating — 4.3; 7.2 units on a scale
N/A N=60 Bronx MBCT-Migraine
Migraine
Primary: Proportion of People With "Severe" Scores on the Migraine Disability Assessment — 77.4; 89.7; 58.1; 75.9 percentage of participants — p=.027
Phase 2 N=84 CHOCOlate MeLatonin for AdolescenT MigrainE
Migraine
Primary: Change in Mean Visual Analog Scale (VAS) Score — -2.3; -2.7 cm
Phase 4 N=25 Erenumab for Idiosyncratic Facial Pain
Facial Pain · Rhinosinusitis
Primary: Change in Mean Number of Days Per Month With Significant Mid-facial Pain or Pressure — -6.0; -5.8 days per month — p=0.96
Phase 2 N=387 A Dose-Finding Study of Topiramate (JNS019) in Participants With Migraine
Migraine
Primary: Mean Change From Baseline in Monthly Migraine Attacks (According to 24-Hour Rule) Through Month 6 — 5.9; 6.2; 6.6; -0.9 Migraine attacks — p=0.1646
Phase 2 N=26 Bringing Relief to Adolescents Naturally Using Melatonin for Migraine
Migraine in Adolescents
Primary: Number of Migraine/Migrainous Days Per 28 Day Period — 3.6; 4.9 days
N/A N=252 Evaluation of a Novel Device for Treatment of Migraine Headache
Migraine Without Aura · Migraine With Aura
Primary: Percentage of Participants With Reduction of Migraine Headache at 2 Hours Post Treatment — 66; 40 Participants
Phase 3 N=58 Occipital Blocks for Acute Migraine
Chronic Migraine, Headache · Episodic Migraine
Primary: Mean Change in Pain Intensity Scores Measured by the Numeric Analog Scale (NRS) — 2.3; 1.1 score on a scale — p=0.013
Phase 3 N=473 Treatment of Multiple Attacks of Acute Migraine (0462-025)
Migraine Headache
Primary: Pain Relief at 2 Hours During the First Migraine Attack Period — 246; 30; 74; 52 participants
Phase 2 N=16 Treatment for Migraine and Mood (Team-M)
Migraine · Depression
Primary: Treatment Session Adherence Rate — 7.88; 8 Number of sessions attended
N/A N=568 Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
Migraine · Episodic Migraine · Headache
Primary: Change in MMD (Monthly Migraine Days) — -3.04; -2.14 migraine days per month
Phase 3 N=865 Migraine Study in Adolescent Patients
Migraine Disorders
Primary: Number of Participants Who Were Pain Free at 2 Hours Post-dose — 14; 28; 26; 36 participants — p=0.003
Phase 3 N=902 Phase 3 Study of MAP0004 in Adult Migraineurs
Migraine Disorders
Primary: Number of Subjects With Pain Relief at 2 Hours From Time of First Dose — 136; 231 participants
N/A N=120 Comparison of Therapeutic Effects of Greater Occipital Nerve Block, Topiramate, and Flunarizine on Episodic Migraine
Migraine
Primary: Visual Analog Scale — 8.1; 7.9; 7.9; 5.9 score on a scale
Phase 3 N=530 The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine
Migraine Disorders
Primary: Pain Free at Two Hours — 40; 21 participants
N/A N=18 Clinical Decision Support for Patient Migraine Management
Migraine
Primary: Adherence to Acute Migraine Management Strategies: Treat Early — 0; 2 Participants
Phase 3 N=205 Headache in the Emergency Department (ED) - A Multi-Center Research Network to Optimize the ED Treatment of Migraines
Migraine
Primary: Persistent Headache Pain Free at 24 Hours — 26; 19 Participants
N/A N=230 PREMIUM Migraine Trial
Migraine Headaches · Patent Foramen Ovale
Primary: Primary Efficacy Endpoint - Percentage of Subjects With a 50% Reduction From Baseline in the Monthly Number of Migraine Attacks at 12 Months. — 32; 38 percentage of…